SINGAPORE (Sept 10): Biolidics has entered into an agreement with the Genome Institute of Singapore (GIS) to collaborate and develop a new and innovative liquid biopsy test in the field of circulating tumour cells (CTCs) for the assessment of minimal residual disease (MRD) and predicting the risk of relapse in women who had breast cancer.
Biolidics is the medical technology company with a focus on cancer diagnostic solutions while GIS is a unit of the Agency for Science, Technology and Research (A*STAR).
Researchers from GIS have previously identified a set of biomarkers, which identify breast cancer patients with higher likelihood of breast cancer relapse within five years.
Separate studies in the US independently report that the surveillance of CTCs presence in blood from early stage breast cancer women post-surgery allows identification of those at a significant higher risk of relapses. With Biolidics’ patented technology, its ClearCell FX1 System can perform liquid biopsies to test for the presence of cancer cells in blood samples.
The latest news follows a Monday announcement Biolidics was collaborating with Hangzhou Normal University to undertake clinical investigations to validate the clinical utility of CTCs as a biomarker in late stage lung cancer.
Shares in Biolidics last traded at 26 cents.
